About Saros Therapeutics

Founded with a mission to revolutionize cancer treatment, Saros Therapeutics is advancing a platform technology to target innate immune cells. Our approach has made us a leading innovator in the field of immunotherapy for cancer and with an ability to target auto-immune diseases. Today, we are dedicated to developing novel therapies that harness or re-direct the power of the immune system to address significant unmet need in both cancer and auto-immune diseases.

Saros’ platform leverages phagocytosis to achieve innate immune cell targeting and is capable of delivering a wide range of compounds that initiate robust immune responses. The technology was invented in the Moon lab at the University of Michigan which is recognized for their world leading expertise in lipid nanoparticles.

The lead nanoparticle formulation targets the STING pathway for immuno-oncology and overcomes the challenges of prior STING programs through proper innate immune cell targeting. With robust efficacy data, a wide therapeutic index and a scalable manufacturing process, the company is working to complete a first IND filing and begin a first-in-human trial in solid tumors.

Our goal is to improve and extend the lives of cancer patients through innovative and safe therapeutic solutions. We believe that our approach exhibits curative potential for patients.